sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib

Identification and characterization of a new member of the TNF family that induces apoptosis

Steven R. Wiley, Ken Schooley, Pamela J. Smolak et al. · Immunity · 1995 · 2.9K citations · Full text

Inflammation, Cytokine, Signaling Pathway +12

Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

Henning Walczak, Robert E. Miller, K. Ariail et al. · Nature Medicine · 1999 · 2.5K citations

Inflammation, Anti-inflammatory, Medicine +9

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · New England Journal of Medicine · 2010 · 1.8K citations · Full text

Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting

Shyh‐Dar Li, Leaf Huang · Journal of Controlled Release · 2010 · 549 citations · Full text

Nanoparticles, Nanomedicine, High Density +10

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 437 citations